Jung, Seungyeon http://orcid.org/0000-0001-8407-9411
Armstrong, Emma
Wei, Alexander Z.
Ye, Fei
Lee, Aaron
Carlino, Matteo S.
Sullivan, Ryan J.
Carvajal, Richard D.
Shoushtari, Alexander N. http://orcid.org/0000-0002-8065-4412
Johnson, Douglas B. http://orcid.org/0000-0002-6390-773X
Article History
Received: 29 March 2022
Revised: 19 July 2022
Accepted: 29 July 2022
First Online: 23 August 2022
Competing interests
: DBJ is on advisory boards or consults for BMS, Catalyst, Iovance, Jansen, Mallinckrodt, Merck, Mosaic ImmunoEngineering, Novartis, Oncosec, Pfizer, and Targovax, and receives research funding from BMS and Incyte. ANS has been on advisory boards or a consultant for Bristol-Myers Squibb, Immunocore, and Novartis and has received research funding from Bristol-Myers Squibb, Immunocore, Novartis, Xcovery, Targovax, Polaris, Pfizer, Checkmate Pharmaceuticals, and Forhorn Therapeutics. RJS has been on advisory boards or a consultant over the last 36 months for BMS, Eisai, Iovance, Merck, Novartis, OncoSec, Pfizer, and has received research funding from Amgen and Merck. RDC has been on advisory boards or a consultant for BMS, Castle Biosciences, Compugen, Foundation Medicine, Immunocore, I-Mab, Incyte, Merck, Roche/Genentech, PureTech Health, Sanofi Genzyme, Sorrento Therapeutics, Rgenix, Chimeron, and Aura Biosciences. He has received research funding from Amgen, Astellis, AstraZeneca, Bayer, Bellicum, BMS, Corvus, Eli Lilly, Immunocore, Incyte, Macrogenics, Merck, Mirati, Novartis, Pfizer, Plexxikon, and Roche/Genentech. EA, SJ, and AZW have no conflicts of interest to report.
: Institutional review board approval was received for study protocols from each institution.
: Not applicable.